Page last updated: 2024-08-21

alpha-aminopyridine and Bilirubinemia

alpha-aminopyridine has been researched along with Bilirubinemia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Attar, EC; Collins, R; de Botton, S; DiNardo, CD; Fathi, AT; Frattini, MG; Kantarjian, HM; MacBeth, KJ; Pollyea, DA; Roboz, GJ; See, WL; Sekeres, MA; Stein, EM; Stone, RM; Tallman, MS; Tosolini, A; Xu, Q	1

Trials

1 trial(s) available for alpha-aminopyridine and Bilirubinemia

Article	Year
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. The Lancet. Haematology, 2020, Volume: 7, Issue:4 Topics: Aged; Aminopyridines; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hyperbilirubinemia; Isocitrate Dehydrogenase; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Triazines	2020

Article

Year

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.

The Lancet. Haematology, 2020, Volume: 7, Issue:4

Topics: Aged; Aminopyridines; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hyperbilirubinemia; Isocitrate Dehydrogenase; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome; Triazines

2020